SKELID is a bisphosphonate characterized by a (4-chlorophenylthio) group on the carbon atom of the basic P-C-P structure common to all bisphosphonates. Its generic name is tiludronate disodium. Tiludronate disodium is the hydrated hemihydrate form of the disodium salt of tiludronic acid.
SKELID is indicated for treatment of Paget's disease of bone (osteitis deformans).
Treatment is indicated in patients with Paget's disease of bone (1) who have a level of serum alkaline phosphatase (SAP) at least twice the upper limit of normal, or (2) who are symptomatic, or (3) who are at risk for future complications of their disease.
Media Articles Related to Skelid (Tiludronate)
Source: MedicineNet Deafness Specialty [2015.11.09]
Title: Paget's Disease
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 11/9/2015 12:00:00 AM
Paget's disease: Gene study pinpoints process that triggers painful bone disease
Source: Arthritis / Rheumatology News From Medical News Today [2015.10.29]
Scientists have pinpointed the mechanism by which a key gene contributes to the development of a painful bone disease.
Published Studies Related to Skelid (Tiludronate)
Tiludronate infusion in the treatment of bone spavin: a double blind placebo-controlled trial. [2010.07]
REASONS FOR PERFORMING STUDY: Tiludronate regulates bone remodelling through a decrease of the resorptive process and should therefore ameliorate the remodelling processes active in osteoarthritis of the distal tarsal joints ('bone spavin') and alleviate pain associated with abnormal bone lysis. OBJECTIVE: To confirm the efficacy of tiludronate, administered as a single infusion at a dose of 1 mg/kg bwt, in the treatment of bone spavin in the horse... CONCLUSIONS: Tiludronate treatment is proven to be effective in bone spavin in horses in association with a controlled exercise programme. CLINICAL RELEVANCE: Tiludronate in combination with controlled exercise offers an alternate medical treatment for bone spavin.
Tiludronate infusion in the treatment of bone spavin: a double blind
placebo-controlled trial. 
infusion at a dose of 1 mg/kg bwt, in the treatment of bone spavin in the horse... CONCLUSIONS: Tiludronate treatment is proven to be effective in bone spavin in
Efficacy of tiludronate in the treatment of horses with signs of pain associated with osteoarthritic lesions of the thoracolumbar vertebral column. [2007.03]
OBJECTIVE: To evaluate the efficacy of tiludronate for the treatment of horses with signs of pain associated with lesions of the thoracolumbar vertebral column. ANIMALS: 29 horses with clinical manifestations of pain associated with lesions of the thoracolumbar vertebral column and abnormal radiographic findings indicative of osteoarthritis of the articular processes-synovial intervertebral joints...
Tiludronate treatment improves structural changes and symptoms of osteoarthritis in the canine anterior cruciate ligament model. [2011.06.21]
INTRODUCTION: The aim of this prospective, randomized, controlled, double-blind study was to evaluate the effects of tiludronate (TLN), a bisphosphonate, on structural, biochemical and molecular changes and function in an experimental dog model of osteoarthritis (OA)... CONCLUSION: Tiludronate treatment demonstrated a positive effect on gait disability and joint symptoms. This is likely related to the positive influence of the treatment at improving some OA structural changes and reducing the synthesis of catabolic and inflammatory mediators.
Comparative pharmacokinetics of two intravenous administration regimens of tiludronate in healthy adult horses and effects on the bone resorption marker CTX-1. [2008.04]
Bioavailability and pharmacological effects of tiludronate were compared when administered as an intravenous (i.v.) bolus at a dosage of 0.1 mg/kg body weight (b.w.) once daily for 10 consecutive days (group 1, n = 6) and as a single constant rate infusion (CRI) at a total dose of 1 mg/kg b.w...
Clinical Trials Related to Skelid (Tiludronate)
Therapeutic Efficacy of Tiludronic Acid on Inner Ear Involvement in Advanced Otosclerosis [Active, not recruiting]
Biomarker Identification in Orthopaedic & Oral Maxillofacial Surgery Subjects to Identify Risks of Bisphosphonate Use [Recruiting]
Bisphosphonates are drugs that prevent bone loss by blocking the activity of cells that
normally resorb bone. The most common examples of these drugs are Boniva and Fosamax. These
drugs are available for oral or intravenous dosing and are prescribed at daily, weekly,
biweekly, or monthly intervals. Among the many thousands of individuals who currently take
these medications, certain individuals experience "atypical" femur fractures preceded by
prodromal pain, changes in cortical thickening of bone, or bisphosphonate related
osteonecrosis of the jaws (BRONJ). Osteonecrosis of the jaws is defined as exposed bone of
the jaws for 8 weeks or more and requires surgical treatment.
This study will attempt to identify genomic and rna biomarkers that may play a role in
differential metabolism of bisphosphonates or indicate tendency toward the severe adverse
events associated with these drugs.